<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00741156</url>
  </required_header>
  <id_info>
    <org_study_id>1000012255</org_study_id>
    <nct_id>NCT00741156</nct_id>
  </id_info>
  <brief_title>The Acute Effects of the Angiotensin-converting Enzyme Inhibitor Enalaprilat on Flow Distribution</brief_title>
  <official_title>The Acute Effects of the Angiotensin-converting Enzyme Inhibitor Enalaprilat on Flow Distribution After the Bidirectional Cavopulmonary Connection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Hospital for Sick Children</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Hospital for Sick Children</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to study the acute effects of angiotensin-converting
      enzyme inhibitor (ACEI) on systemic, pulmonary and cerebral blood flow in post bidirectional
      cavopulmonary connection (BCPC) patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The intermediate stage of the bi-directional cavopulmonary connection (BCPC) in the
      management algorithm of single ventricle palliation is a unique and extraordinary physiologic
      condition. It places the superior vena caval blood flow into series with the lungs i.e.
      pulmonary blood flow is partially dependent on cerebral vascular flow and resistance.
      Differential reduction in the resistances of the systemic, cerebral and pulmonary vascular
      beds will result in re-equilibrium of relative blood flows which translate to alterations in
      arterial oxygen tension and perfusion pressure. This concept is demonstrated by the
      differential effects of carbon dioxide (CO2) and oxygen (O2). CO2 vasodilates and oxygen (O2)
      vasoconstricts the cerebral vascular bed; the opposite is true in the lungs. Furthermore,
      studies have demonstrated that arterial CO2 tension (PaCO2) at hypercarbic levels is
      favourable to normocarbia in increasing pulmonary, systemic and cerebral blood flows and
      reducing systemic vascular resistance in acute post BCPC patients.

      Administration of angiotensin-converting enzyme inhibitor (ACEI) and other systemic
      vasodilator drugs are well established for treatment of patients with hypertension and
      congestive cardiomyopathy in both pediatric and adult populations. Favourable manipulation of
      the flow to the different vascular beds has been reported in children with significant
      intra-cardiac shunts in which pulmonary blood flow is decreased relative to the increase in
      systemic blood flow as a result of reduction of systemic vascular resistance.

      Guided by similar principles, ACEI therapy is administered to patients with single ventricle
      physiology to redistribute relative blood flows across the pulmonary and systemic vascular
      beds. To date, there exists no study examining the hemodynamic effects of ACEI on relative
      blood flows in the setting of single ventricle physiology and in particular, no study
      demonstrates its benefits. The effects of ACEI are unknown on the equilibrium of relative
      cerebral, systemic and pulmonary blood flows in the post-BCPC state. A relative increase in
      systemic blood flow, as effected by ACEI, at the expense of cerebral blood flow may
      potentially adversely decrease pulmonary blood and ultimately reduce arterial oxygen tension.
      On the other hand, some data suggests that ACEI's improve cerebral autoregulation function;
      in which drop in blood pressure will signal a vasodilatory response in the cerebral vascular
      bed which may be particularly advantageous in BCPC patients.

      Enalaprilat is the active diacid of the ACEI enalapril maleate. Doses of 0.01 to 0.06 mg/kg
      i.v. have been safely administered in pediatric studies. Onset of action is 15 minutes and
      duration of action is up to 12-24 hours. The pharmacokinetics of this drug are ideal for the
      purpose of this study. In our institution, all patients undergo routine cardiac
      catheterization after the BCPC procedure for hemodynamic assessment and angiography of
      cardiac structures to assess for eligibility for the Fontan operation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Systemic, Pulmonary and Cerebral Blood Flow at Baseline and After Enalaprilat</measure>
    <time_frame>Baseline and after enalaprilat</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Systemic, Pulmonary and Cerebral Resistance at Baseline and After Enalaprilat</measure>
    <time_frame>Baseline and after enalaprilat</time_frame>
    <description>Systemic, pulmonary and cerebral resistance is compared at baseline and after enalaprilat</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Hypertension</condition>
  <condition>Congestive Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>Enalaprilat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>enalaprilat 0.005-0.01 mg/kg intravenous x 1 dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enalaprilat</intervention_name>
    <description>Enalaprilat will be administered intravenously i.v. 0.005 - 0.01 mg/kg i.v. over 1 minute</description>
    <arm_group_label>Enalaprilat</arm_group_label>
    <other_name>Vasotec</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BCPC patients at time of routine pre-Fontan catheterization

          -  Patients between the ages of 2 months and 5 years old

        Exclusion Criteria:

          -  Patients who have had ACEI therapy within 24 hours of the procedure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>5 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyong-Jin Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Hospital for Sick Children</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 25, 2008</study_first_submitted>
  <study_first_submitted_qc>August 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2008</study_first_posted>
  <results_first_submitted>July 26, 2013</results_first_submitted>
  <results_first_submitted_qc>November 16, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 18, 2015</results_first_posted>
  <last_update_submitted>November 16, 2015</last_update_submitted>
  <last_update_submitted_qc>November 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Hospital for Sick Children</investigator_affiliation>
    <investigator_full_name>Kyong-Jin Lee</investigator_full_name>
    <investigator_title>Staff Cardiologist</investigator_title>
  </responsible_party>
  <keyword>pediatric</keyword>
  <keyword>hypertension</keyword>
  <keyword>congestive cardiomyopathy</keyword>
  <keyword>angiotensin-converting enzyme inhibitor</keyword>
  <keyword>cardiac catheterization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Cardiomyopathy, Dilated</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Enzyme Inhibitors</mesh_term>
    <mesh_term>Enalaprilat</mesh_term>
    <mesh_term>Enalapril</mesh_term>
    <mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Enalaprilat</title>
          <description>Enalaprilat : Enalaprilat will be administered intravenously i.v. 0.01 mg/kg i.v. over 1 minute</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Enalaprilat</title>
          <description>Enalaprilat : Enalaprilat will be administered intravenously i.v. 0.01 mg/kg i.v. over 1 minute</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.3" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">SEX WAS NOT IDENTIFIED</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">SEX WAS NOT IDENTIFIED</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Systemic, Pulmonary and Cerebral Blood Flow at Baseline and After Enalaprilat</title>
        <time_frame>Baseline and after enalaprilat</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Systemic Blood Flow Baseline</title>
            <description>Systemic blood flow in baseline condition</description>
          </group>
          <group group_id="O2">
            <title>Systemic Blood Flow After Enalaprilat</title>
            <description>Systemic blood flow 20 minutes after enalaprilat</description>
          </group>
          <group group_id="O3">
            <title>Pulmonary Blood Flow Baseline</title>
            <description>Pulmonary blood flow baseline condition</description>
          </group>
          <group group_id="O4">
            <title>Pulmonary Blood Flow After Enaliprilat</title>
            <description>Pulmonary blood flow 20 minutes after enalaprilat</description>
          </group>
          <group group_id="O5">
            <title>Cerebral Blood Flow Baseline</title>
            <description>Cerebral blood flow at baseline</description>
          </group>
          <group group_id="O6">
            <title>Cerebral Blood Flow After Enalaprilat</title>
            <description>Cerebral blood flow 20 minutes after enalaprilat</description>
          </group>
        </group_list>
        <measure>
          <title>Systemic, Pulmonary and Cerebral Blood Flow at Baseline and After Enalaprilat</title>
          <units>l/min/m2</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" lower_limit="0.9" upper_limit="1.8"/>
                    <measurement group_id="O2" value="1.8" lower_limit="1.0" upper_limit="2.2"/>
                    <measurement group_id="O3" value="1.9" lower_limit="1.8" upper_limit="2.9"/>
                    <measurement group_id="O4" value="1.9" lower_limit="1.6" upper_limit="2.5"/>
                    <measurement group_id="O5" value="1.9" lower_limit="1.6" upper_limit="2.9"/>
                    <measurement group_id="O6" value="1.8" lower_limit="1.6" upper_limit="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.09</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Systemic, Pulmonary and Cerebral Resistance at Baseline and After Enalaprilat</title>
        <description>Systemic, pulmonary and cerebral resistance is compared at baseline and after enalaprilat</description>
        <time_frame>Baseline and after enalaprilat</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Systemic Resistance at Baseline</title>
            <description>systemic resistance in baseline condition</description>
          </group>
          <group group_id="O2">
            <title>Systemic Resistance After Enalaprilat</title>
            <description>systemic resistance is measured after enalaprilat</description>
          </group>
          <group group_id="O3">
            <title>Pulmonary Resistance at Baseline</title>
            <description>pulmonary resistance at baseline is measured</description>
          </group>
          <group group_id="O4">
            <title>Pulmonary Resistance After Enalaprilat</title>
            <description>pulmonary resistance is measured after enalaprilat</description>
          </group>
          <group group_id="O5">
            <title>Cerebral Resistance at Baseline</title>
            <description>cerebral resistance is measured in baseline condition</description>
          </group>
          <group group_id="O6">
            <title>Cerebral Resistance After Enalaprilat</title>
            <description>cerebral resistance is measured after enalaprilat</description>
          </group>
        </group_list>
        <measure>
          <title>Systemic, Pulmonary and Cerebral Resistance at Baseline and After Enalaprilat</title>
          <description>Systemic, pulmonary and cerebral resistance is compared at baseline and after enalaprilat</description>
          <units>Wood units per metre squared</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.94" lower_limit="26.63" upper_limit="67.83"/>
                    <measurement group_id="O2" value="20.26" lower_limit="16.5" upper_limit="28.16"/>
                    <measurement group_id="O3" value="2.87" lower_limit="1.03" upper_limit="4.47"/>
                    <measurement group_id="O4" value="2.54" lower_limit="0.49" upper_limit="4.76"/>
                    <measurement group_id="O5" value="24.07" lower_limit="15.79" upper_limit="38.1"/>
                    <measurement group_id="O6" value="17.32" lower_limit="13.57" upper_limit="21.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 hours</time_frame>
      <desc>during cardiac catheterization monitoring period.</desc>
      <group_list>
        <group group_id="E1">
          <title>Enalaprilat</title>
          <description>Enalaprilat : Enalaprilat will be administered intravenously i.v. 0.01 mg/kg i.v. over 1 minute</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Kyong-Jin Lee</name_or_title>
      <organization>The Hospital for Sick Children</organization>
      <phone>416-813-7326</phone>
      <email>kyong-jin.lee@sickkids.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

